Find Technologies

  • Reporter Assay for Detection and Quantitation of Replication-Competent Gammaretrovirus
    •
       Ref: E-125-2020 | Updated: Jul 07, 2020 | NCI
  • A peptide hydrogel for use in vascular anastomosis
    •
       Ref: E-292-2014 | Updated: Nov 27, 2019 |
  • Nanoparticle-hydrogel Composite for Nucleic Acid Molecule Delivery
    •
       Ref: E-080-2018 | Updated: May 14, 2019 | NCI
  • Video Monitoring and Analysis System for Vivarium Cage Racks
    •
       Ref: E-090-2013 | Updated: Jul 19, 2018 | NCI
  • Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations
    •
       Ref: E-028-2015 | Updated: Dec 07, 2017 | NCI
  • Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer
    •
       Ref: E-226-2014 | Updated: May 16, 2018 | NCI
  • T cell Receptors Which Recognize Mutated EGFR
    •
       Ref: E-098-2018 | Updated: Oct 12, 2018 | NCI
  • Extremely Rapid Method to Isolate Neoantigen Reactive T Cell Receptors (TCRs)
    •
       Ref: E-061-2020 | Updated: Sep 03, 2020 | NCI
  • Eye Tracking Application in Computer Aided Diagnosis and Image Processing in Radiology
    •
       Ref: E-118-2015 | Updated: Aug 16, 2018 | NIH-CC
  • Composite Gels and Methods of their Use in Tissue Repair, Drug Delivery, and as Implants
    •
       Ref: E-014-2019 | Updated: Oct 27, 2020 | NICHD
  • Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use
    •    Ref: E-077-2019 | Updated: Oct 27, 2020 | NIDA
  • Mobile Software for Substance Abuse Interventions and Behavioral Modification
    •    Ref: E-195-2012 | Updated: Mar 21, 2018 | NIDA
  • Human Cell Line for Studies on Signaling and Endocrine Cancer
    •
       Ref: E-267-2012 | Updated: Jul 19, 2018 | NICHD
  • Silicone Hydrogel Support Structures that Mimic Tissue Vasculature for Cell Culturing
    •
       Ref: E-070-2013 | Updated: Mar 30, 2017 | NCI
  • Antibody and Immunotoxin Treatments for Mesothelin-expressing Cancers
    •    Ref: E-091-2009 | Updated: Jun 29, 2017 | NCI
  • Multivalent Immunogenic Vaccines for Treating Prostate and Breast Cancer
    •
       Ref: E-047-2014 | Updated: Apr 07, 2020 | NCI
  • Quantitative In Vivo Methods for Measuring Brain Networks
    •
       Ref: E-226-2010 | Updated: Nov 08, 2018 | NICHD
  • T-Cell Therapy Against Patient-Specific Cancer Mutations
    •
       Ref: E-233-2014 | Updated: Oct 19, 2020 | NCI
  • HIV-1 Therapeutic Inhibits Viral Entry
    •
       Ref: E-033-2013 | Updated: May 30, 2018 | NCI
  • CNS Therapeutics That Target Neuronal Ceroid-Lipofuscinoses and Thioesterase Deficiency Disorders
    •
       Ref: E-157-2011 | Updated: Nov 09, 2018 | NICHD
  • Zirconium-89 PET Imaging Agent for Cancer
    •
       Ref: E-111-2013 | Updated: Jul 19, 2018 | NCI
  • Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents
    •
       Ref: E-167-2010 | Updated: Aug 31, 2016 | NCI
  • Human Antibody for Deploying CH2-Based Therapeutics
    •
       Ref: E-245-2012 | Updated: Jun 07, 2018 |
  • Novel Fusion Proteins for HIV Vaccine
    •
       Ref: E-256-2012 | Updated: Sep 06, 2016 | NCI
  • T-Cell Therapy Against Patient-Specific Cancer Mutations
    •
       Ref: E-229-2014 | Updated: Feb 03, 2020 | NCI
  • Monoclonal Antibody Fragments for Targeting Therapeutics to Growth Plate Cartilage
    •
       Ref: E-003-2014 | Updated: Aug 07, 2020 | NICHD
  • Human Antibodies Against Middle East Respiratory Syndrome Coronavirus
    •
       Ref: E-002-2014 | Updated: May 30, 2018 | NCI
  • Natural product-based anti-cancer agents: aza-Englerin analogues
    •
       Ref: E-090-2014 | Updated: Dec 20, 2017 | NCI
  • Nanoparticle delivery of lung cancer therapeutic
    •
       Ref: E-159-2014 | Updated: May 18, 2020 | NCI
  • GTF2I Mutations as a Genetic Marker for Prognosis of Thymic Malignancies
    •
       Ref: E-109-2014 | Updated: Aug 31, 2016 | NCI
  • Novel Immunotherapy for Cancer Treatment: Chimeric Antigen Receptors Targeting CD70 Antigen
    •
       Ref: E-021-2015 | Updated: Jul 19, 2018 | NCI
  • Synthetic lipopeptide inhibitors of RAS oncoproteins
    •
       Ref: E-293-2010 | Updated: Aug 31, 2016 | NCI
  • Improved Antibodies Against ERBB4/HER4
    •
       Ref: E-171-2009 | Updated: Apr 20, 2018 | NICHD
  • Topical Antibiotic for Faster Wound Healing
    •
       Ref: E-294-2011 | Updated: Apr 07, 2020 | NCI
  • High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research
    •
       Ref: E-136-2012 | Updated: Apr 24, 2018 | NCI
  • Knockout and Conditional Knockout Mice-GPR116
    •    Ref: E-269-2012 | Updated: Apr 23, 2018 | NCI
  • High-Affinity Rabbit Monoclonal Antibodies for Cancer Treatment
    •
       Ref: E-198-2012 | Updated: Sep 06, 2016 | NCI
  • Anti-Mesothelin Monoclonal Antibodies for the Treatment of Cancer
    •
       Ref: E-236-2012 | Updated: Jun 07, 2018 | NCI
  • Non-invasive diagnostic and prognostic assay for early stage lung cancer
    •
       Ref: E-121-2013 | Updated: Dec 20, 2017 | NCI
  • Ex-vivo Production of Regulatory B-Cells for Use in Auto-immune Diseases
    •
       Ref: E-036-2012 | Updated: Apr 13, 2020 | NEI
  • Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
    •
       Ref: E-211-2016 | Updated: Dec 19, 2018 | NCI
  • Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles
    •
       Ref: E-098-2015 | Updated: Oct 02, 2019 | NCI
  • High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
    •
       Ref: E-198-2018 | Updated: Oct 15, 2018 | NCI
  • High Affinity Monoclonal Antibodies Targeting Glypican-1
    •    Ref: E-028-2019 | Updated: Dec 10, 2019 | NCI
  • High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin
    •
       Ref: E-040-2019 | Updated: May 15, 2019 | NCI
  • Polypeptides for Stimulation of Immune Response (Adjuvants)
    •
       Ref: E-185-2008 | Updated: Jul 13, 2018 | NCI
  • Diagnostic for Cancer of the Adrenal Glands and Adrenal Cortex
    •
       Ref: E-135-2012 | Updated: Aug 10, 2020 | NCI
  • GATA-3 Reporter Plasmids for Revealing Underlying Mechanisms in Breast Cancer
    •
       Ref: E-128-2009 | Updated: Apr 07, 2020 | NCI
  • Nanoparticles for the targeted treatment of infected cells
    •
       Ref: E-039-2012 | Updated: Jun 08, 2018 | NCI
  • Treatment of Prostate Cancer Using Anti-androgen Small Molecules
    •
       Ref: E-015-2011 | Updated: Nov 27, 2018 | NCI
  • Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)
    •
       Ref: E-094-2018 | Updated: Oct 15, 2018 | NCI
  • Device for Growing Mammalian Cells on EM Grids
    •
       Ref: E-243-2016 | Updated: Dec 20, 2017 | NCI
  • Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain
    •
       Ref: E-094-2013 | Updated: Apr 18, 2018 | NCI
  • Peptide Mimetic Ligands of Polo-like Kinase 1 Polo Box Domain (“Plk1 PBD Portfolio”)
    •
       Ref: E-181-2009 | Updated: Feb 16, 2018 | NCI
  • Tumor Samples Harboring Novel Stem Cell Factor FOXD3 Variants
    •
       Ref: E-058-2010 | Updated: Jul 19, 2018 | NICHD
  • Increased Therapeutic Effectiveness of PE-Based Immunotoxins
    •
       Ref: E-263-2011 | Updated: Aug 31, 2016 | NCI
  • Mouse Model for the Preclinical Study of Metastatic Disease
    •
       Ref: E-296-2012 | Updated: Jun 07, 2018 | NCI
  • Chimeric Antigen Receptors that Recognize Mesothelin for Cancer Immunotherapy
    •
       Ref: E-078-2012 | Updated: Oct 11, 2017 | NCI
  • Monoclonal Antibodies and Immunoconjugates Directed to the Non-ShedPortion (“Stalk”) of Mesothelin are Excellent Candidates for Developing Therapeutic Agents
    •
       Ref: E-106-2017 | Updated: Apr 26, 2019 | NCI
  • New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity
    •
       Ref: E-231-2017 | Updated: Aug 01, 2019 | NCI
  • Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity
    •
       Ref: E-179-2019 | Updated: Aug 17, 2020 | NCI
  • New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies
    •    Ref: E-016-2018 | Updated: Aug 03, 2018 | NCI, CCR, LMB
  • High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
    •
       Ref: E-185-2019 | Updated: Aug 17, 2020 | NCI
  • HIV-1 Env Fusion Peptide Immunogens and Their Use
    •
       Ref: E-279-2016-0 | Updated: Oct 17, 2018 | NIAID
  • Reprogrammed Tumor Infiltrated Lymphocytes for Efficient Identification of Tumor-Antigen Specific T-Cell Receptors
    •
       Ref: E-091-2019 | Updated: Mar 04, 2020 | NCI
  • T-Cell Receptors Targeting Epstein Barr Virus Latent Membrane Protein 2 for Treatment of Lymphomas and Epithelial Cancer
    •
       Ref: E-121-2020 | Updated: May 08, 2020 | NCI
  • Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members
    •
       Ref: E-100-2020 | Updated: Apr 30, 2020 | NEI
  • Inducible Activation Nucleic Acid Hybrid Switch for Conditional Generation of Oligonucleotides
    •
       Ref: E-065-2019 | Updated: May 01, 2020 | NCI
  • Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation
    •
       Ref: E-113-2018 | Updated: Aug 24, 2020 | NCI
  • Improved CD22 Binders for Effective Immunotherapy Against Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    •
       Ref: E-161-2018 | Updated: Jun 30, 2020 | NCI
  • Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy
    •    Ref: E-195-2018 | Updated: Aug 01, 2019 | NCI/Leidos
  • Autophagy Modulators For Use in Treating Cancer
    •
       Ref: E-003-2018 | Updated: Aug 06, 2020 | NICHD
  • Design and Biological Activity of Novel Stealth Polymeric Lipid Nanoparticles for Enhanced Delivery of Hydrophobic Photodynamic Therapy Drugs
    •
       Ref: E-154-2018 | Updated: Nov 19, 2019 | NCI
  • Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
    •
       Ref: E-172-2017 | Updated: Jan 15, 2020 | NCI
  • Combined PIKFYVE and p38 MAP Kinase Inhibition for Treating Cancer
    •    Ref: E-138-2019 | Updated: Apr 20, 2020 | NICHD
  • Therapeutic Antitumor Combination Containing TLR4 Agonist HMGN1
    •    Ref: E-069-2016 | Updated: Oct 15, 2018 | NCI
  • New Insect Sf9-ET Cell Line for Determining Baculovirus Titers
    •
       Ref: E-009-2008 | Updated: Oct 15, 2018 | NCI
  • Self-Assembling Nanoparticles Composed of Transmembrane Peptides and Their Application for Specific Intra-Tumor Delivery of Anti-Cancer Drugs
    •    Ref: E-256-2006 | Updated: Oct 23, 2018 | NCI
  • Non-Invasive In Vivo MRI Method to Image Salient Features of Axons and Nerves
    •    Ref: E-079-2003 | Updated: Nov 14, 2018 | NICHD
  • Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells
    •
       Ref: E-250-2016 | Updated: Aug 13, 2020 | NCI
  • Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer
    •
       Ref: E-258-2016 | Updated: Jun 10, 2019 | NCI
  • Recombinant Virus Vectors for the Treatment of Glycogen Storage Disease type Ib (GSD-Ib)
    •
       Ref: E-072-2017 | Updated: May 15, 2019 | NICHD
  • In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells
    •
       Ref: E-133-2017 | Updated: Sep 18, 2019 | NCI
  • Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use
    •
       Ref: E-132-2017 | Updated: Sep 18, 2019 | NCI
  • Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies
    •
       Ref: E-174-2012 | Updated: Apr 07, 2020 | NCI
  • Bone Marrow Mesenchymal Stem Cell (BMSC)-Derived Exosomes for the Treatment of Glaucoma
    •
       Ref: E-044-2018 | Updated: Aug 16, 2018 | NEI
  • Transformation of Weak or Non-Immunogenic Antigens to Produce an Immune Response and Therapeutic Polypeptides for the Treatment and Prevention of Cancer
    •
       Ref: E-271-2006 | Updated: Aug 23, 2018 | NIA
  • Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV
    •
       Ref: E-103-2010 | Updated: Sep 05, 2018 |
  • Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy
    •
       Ref: E-065-2017 | Updated: Sep 05, 2018 | NCI
  • Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus
    •    Ref: E-287-2012 | Updated: Oct 01, 2018 | NCI
  • Multi-Foci Sonications For Hyperthermia Treatments Using Magnetic Resource-Guided High-Intensity Focused Ultrasound (MR-HIFU)
    •
       Ref: E-013-2013 | Updated: Oct 12, 2018 | NIH CC
  • Methods For Treating or Preventing Inflammation and Periodontitis
    •
       Ref: E-015-2018 | Updated: Oct 12, 2018 | NCI
  • Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
    •
       Ref: E-229-2017 | Updated: Oct 12, 2018 | NCI
  • Tethered Interleukin-15 (IL-15)/IL-21 to Enhance T Cells for Cellular Therapy
    •
       Ref: E-068-2018 | Updated: Oct 12, 2018 | NCI
  • The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof
    •
       Ref: E-244-2004 | Updated: Oct 12, 2018 | NCI
  • Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells
    •
       Ref: E-138-2006 | Updated: Oct 12, 2018 | NCI
  • Agonist Epitopes for the Development of a Human Papillomavirus (HPV) Therapeutic Vaccine
    •
       Ref: E-169-2016 | Updated: Oct 12, 2018 | NCI
  • Targeted RNA/DNA Nanoparticles with Single Stranded RNA Toeholds
    •
       Ref: E-078-2016 | Updated: Jul 27, 2018 | NCI
  • Fusion Proteins as HIV-1 Entry Inhibitors
    •
       Ref: E-086-2015 | Updated: Jul 27, 2018 | NCI
  • Conformational Restriction of Cyanine Fluorophores in Far-Red and Near-IR Range
    •
       Ref: E-143-2017 | Updated: Jul 27, 2018 | NCI

    Pages


    Displaying 1101 - 1200 of 1372

    Category Index

    Office of Technology Transfer, Office of Intramural Research, National Institutes of Health

    6011 Executive Blvd, Suite 325, Rockville, MD 20852 | Phone: 301-496-7057